Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AH-001 topical formulation in healthy volunteers and androgenetic alopecia
NCT06927960Phase 1Completed
- Sponsor
- AnHorn Medicines
- Start
- Mar 2025
- Primary completion
- Jul 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AH-001 in androgenetic alopecia (AGA) (4 arms), sponsored by AnHorn Medicines. Primary endpoints: Treatment-Emergent Adverse Events, Changes from Baseline in Local Skin Reaction and 3 more. Started Mar 2025; status: completed.
02
Drugs
AH-001
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT06927960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06927960.